Stephanie A Richard1,2, Nusrat J Epsi1,2, Simon Pollett1,2, David A Lindholm3,4, Allison M W Malloy4, Ryan Maves1,5, Gregory C Utz1,2,5, Tahaniyat Lalani1,2,6, Alfred G Smith6, Rupal M Mody7, Anuradha Ganesan1,2,8, Rhonda E Colombo1,2,9, Christopher J Colombo4,9, Sharon W Chi1,2,10, Nikhil Huprikar4,8, Derek T Larson4,11, Samantha Bazan12, Cristian Madar10, Charlotte Lanteri1, Julia S Rozman1,2, Caroline English1,2, Katrin Mende1,2,3, David R Tribble1, Brian K Agan1,2, Timothy H Burgess1, John H Powers13. 1. Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. 2. The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA. 3. Brooke Army Medical Center, Fort Sam Houston, Texas, USA. 4. Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. 5. Naval Medical Center San Diego, San Diego, California, USA. 6. Naval Medical Center Portsmouth, Portsmouth, Virginia, USA. 7. William Beaumont Army Medical Center, El Paso, Texas, USA. 8. Walter Reed National Military Medical Center, Bethesda, Maryland, USA. 9. Madigan Army Medical Center, Joint Base Lewis McChord, Washington, USA. 10. Tripler Army Medical Center, Honolulu, Hawaii, USA. 11. Fort Belvoir Community Hospital, Fort Belvoir, Virginia, USA. 12. Carl R. Darnall Army Medical Center, Fort Hood, Texas, USA. 13. Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Abstract
BACKGROUND: The inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) is a patient-reported outcome data collection instrument assessing symptoms of viral respiratory tract infections across 8 body systems. This study evaluated the measurement properties of FLU-PRO Plus in a study enrolling individuals with coronavirus disease 2019 (COVID-19). METHODS: Data from a prospective cohort study (EPICC) in US Military Health System beneficiaries evaluated for COVID-19 was utilized. Adults with symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with FLU-PRO Plus survey information within 1 week of symptom onset were included. Reliability of FLU-PRO Plus was estimated using intraclass correlation coefficient (ICC; 2 days' reproducibility). Known-groups validity was assessed using patient global assessment (PGA) of disease severity. Patient report of return to usual health was used to assess responsiveness (day 1-6/7). RESULTS: Two hundred twenty-six SARS-CoV-2-positive participants were included in the analysis. Reliability among those who reported no change in their symptoms from one day to the next was high for most domains (ICC range, 0.68-0.94 for day 1 to day 2). Construct validity was demonstrated by moderate to high correlation between the PGA rating of disease severity and domain and total scores (eg, total scores correlation: 0.69 [influenza-like illness severity], 0.69 [interference in daily activities], and -0.58 [physical health]). In addition, FLU-PRO Plus demonstrated good known-groups validity, with increasing domain and total scores observed with increasing severity ratings. CONCLUSIONS: FLU-PRO Plus performs well in measuring signs and symptoms in SARS-CoV-2 infection with excellent construct validity, known-groups validity, and responsiveness to change. Standardized data collection instruments facilitate meta-analyses, vaccine effectiveness studies, and other COVID-19 research activities. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2021.
BACKGROUND: The inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) is a patient-reported outcome data collection instrument assessing symptoms of viral respiratory tract infections across 8 body systems. This study evaluated the measurement properties of FLU-PRO Plus in a study enrolling individuals with coronavirus disease 2019 (COVID-19). METHODS: Data from a prospective cohort study (EPICC) in US Military Health System beneficiaries evaluated for COVID-19 was utilized. Adults with symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with FLU-PRO Plus survey information within 1 week of symptom onset were included. Reliability of FLU-PRO Plus was estimated using intraclass correlation coefficient (ICC; 2 days' reproducibility). Known-groups validity was assessed using patient global assessment (PGA) of disease severity. Patient report of return to usual health was used to assess responsiveness (day 1-6/7). RESULTS: Two hundred twenty-six SARS-CoV-2-positive participants were included in the analysis. Reliability among those who reported no change in their symptoms from one day to the next was high for most domains (ICC range, 0.68-0.94 for day 1 to day 2). Construct validity was demonstrated by moderate to high correlation between the PGA rating of disease severity and domain and total scores (eg, total scores correlation: 0.69 [influenza-like illness severity], 0.69 [interference in daily activities], and -0.58 [physical health]). In addition, FLU-PRO Plus demonstrated good known-groups validity, with increasing domain and total scores observed with increasing severity ratings. CONCLUSIONS: FLU-PRO Plus performs well in measuring signs and symptoms in SARS-CoV-2 infection with excellent construct validity, known-groups validity, and responsiveness to change. Standardized data collection instruments facilitate meta-analyses, vaccine effectiveness studies, and other COVID-19 research activities. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2021.
Authors: John H Powers; Elizabeth D Bacci; Nancy K Leidy; Jiat-Ling Poon; Sonja Stringer; Matthew J Memoli; Alison Han; Mary P Fairchok; Christian Coles; Jackie Owens; Wei-Ju Chen; John C Arnold; Patrick J Danaher; Tahaniyat Lalani; Timothy H Burgess; Eugene V Millar; Michelande Ridore; Andrés Hernández; Patricia Rodríguez-Zulueta; Hilda Ortega-Gallegos; Arturo Galindo-Fraga; Guillermo M Ruiz-Palacios; Sarah Pett; William Fischer; Daniel Gillor; Laura Moreno Macias; Anna DuVal; Richard Rothman; Andrea Dugas; M Lourdes Guerrero Journal: PLoS One Date: 2018-03-22 Impact factor: 3.240
Authors: Jerome R Lechien; Fabrice Journe; Stephane Hans; Carlos M Chiesa-Estomba; Vincent Mustin; Eline Beckers; Luigi A Vaira; Giacomo De Riu; Claire Hopkins; Sven Saussez Journal: Front Med (Lausanne) Date: 2020-11-24
Authors: John H Powers; Elizabeth D Bacci; M Lourdes Guerrero; Nancy Kline Leidy; Sonja Stringer; Katherine Kim; Matthew J Memoli; Alison Han; Mary P Fairchok; Wei-Ju Chen; John C Arnold; Patrick J Danaher; Tahaniyat Lalani; Michelande Ridoré; Timothy H Burgess; Eugene V Millar; Andrés Hernández; Patricia Rodríguez-Zulueta; Mary C Smolskis; Hilda Ortega-Gallegos; Sarah Pett; William Fischer; Daniel Gillor; Laura Moreno Macias; Anna DuVal; Richard Rothman; Andrea Dugas; Guillermo M Ruiz-Palacios Journal: Value Health Date: 2017-06-07 Impact factor: 5.725
Authors: Rachel M Burke; Marie E Killerby; Suzanne Newton; Candace E Ashworth; Abby L Berns; Skyler Brennan; Jonathan M Bressler; Erica Bye; Richard Crawford; Laurel Harduar Morano; Nathaniel M Lewis; Tiffanie M Markus; Jennifer S Read; Tamara Rissman; Joanne Taylor; Jacqueline E Tate; Claire M Midgley Journal: MMWR Morb Mortal Wkly Rep Date: 2020-07-17 Impact factor: 17.586
Authors: David A Drew; Long H Nguyen; Tim D Spector; Andrew T Chan; Claire J Steves; Cristina Menni; Maxim Freydin; Thomas Varsavsky; Carole H Sudre; M Jorge Cardoso; Sebastien Ourselin; Jonathan Wolf Journal: Science Date: 2020-05-05 Impact factor: 47.728
Authors: Hassan Bencheqroun; Yasir Ahmed; Mehmet Kocak; Enrique Villa; Cesar Barrera; Mariya Mohiuddin; Raul Fortunet; Emmanuel Iyoha; Deborah Bates; Chinedu Okpalor; Ola Agbosasa; Karim Mohammed; Stephen Pondell; Amr Mohamed; Yehia I Mohamed; Betul Gok Yavuz; Mohamed O Kaseb; Osama O Kasseb; Michelle York Gocio; Peter Tsu-Man Tu; Dan Li; Jianming Lu; Abdulhafez Selim; Qing Ma; Ahmed O Kaseb Journal: Pathogens Date: 2022-05-07
Authors: Stephanie A Richard; Nusrat J Epsi; David A Lindholm; Allison M W Malloy; Ryan C Maves; Catherine M Berjohn; Tahaniyat Lalani; Alfred G Smith; Rupal M Mody; Anuradha Ganesan; Nikhil Huprikar; Rhonda E Colombo; Christopher J Colombo; Cristian Madar; Milissa U Jones; Derek T Larson; Evan C Ewers; Samantha Bazan; Anthony C Fries; Carlos J Maldonado; Mark P Simons; Julia S Rozman; Liana Andronescu; Katrin Mende; David R Tribble; Brian K Agan; Timothy H Burgess; Simon D Pollett; John H Powers Journal: Open Forum Infect Dis Date: 2022-06-07 Impact factor: 4.423
Authors: Carla Romano; Sheri Fehnel; Jeffrey Stoddard; Jerald Sadoff; Sandy Lewis; Pauline McNulty; Eric K H Chan; Emily Evans; Carol Jamieson; Ashley F Slagle; Allen Mangel; Kelly McQuarrie Journal: J Patient Rep Outcomes Date: 2022-07-29